Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib plus gemcitabine/platinum vs placebo plus gemcitabine/platinum in first-line advanced NSCLC
CTR20131154Phase 3Active
- Sponsor
- Roche
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Erlotinib plus gemcitabine/platinum with Placebo plus gemcitabine/platinum (2 arms). Primary endpoint: Progression-free survival. Started Nov 2013; status: active.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20131154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131154.